Quantcast

Latest Biological warfare Stories

2014-03-10 12:25:52

PINE BROOK, N.J., March 10, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/076,082, granting a patent which covers methods of preventing or treating anthrax with ETI-204, the company's anti-anthrax antibody, together with antibiotics. The patent also...

2014-03-05 08:20:33

Hawaii Biotech Receives DoD Contract to Develop Anti-Botulism Drug HONOLULU, March 5, 2014 /PRNewswire/ -- The Department of Defense, Defense Threat Reduction Agency, has awarded Hawaii Biotech, Inc., a contract to continue developing drugs to block botulinum toxin, the toxin that causes the life-threatening disease, botulism. There is no therapeutic drug currently available for the treatment of botulism. The award has a first-year period of performance through early 2014, followed...

2014-02-14 08:25:55

Soligenix Initiates Medical Countermeasure Development of SGX943 PRINCETON, N.J., Feb. 14, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has...

2014-02-05 08:28:42

Presentation to be Webcast Live on February 10, 2014 at 3 PM EST PRINCETON, N.J., Feb. 5, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD,...

2014-02-04 12:28:56

HONOLULU, Feb. 4, 2014 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech, Inc. a grant to continue the development of anthrax anti-toxin drugs. The small molecule inhibitors under development block anthrax lethal toxin. The award has a first-year period of performance, through Q1 2014, valued at $1.1 million. The grant for the full five-year period equals $7.4 million. Under...

2014-01-29 08:23:33

The ability to remediate buildings following a weaponized biological attack may have been achieved with AsepticSure® SAN FRANCISCO, Jan. 29, 2014 /PRNewswire/ -- Medizone International, Inc. (The Company) (MZEI:OB, MZEI:QB) has just been granted its fourth patent for its revolutionary enclosed space room disinfection system, AsepticSure. The United States Patent and Trademark Office has issued US Patent number 8,636,951 titled BIO-TERRORISM COUNTERACTION USING OZONE AND HYDROGEN...

2014-01-16 08:26:49

Receipt of Proceeds increases January Cash Position to Approximately $6.6 million PRINCETON, N.J., Jan. 16, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of...

2014-01-15 08:27:45

Milestone Achieved under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., Jan. 15, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary...

2014-01-09 08:27:11

Presentation to be Webcast Live on January 14, 2014 at 11AM PST PRINCETON, N.J., Jan. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD,...

2014-01-07 12:21:37

Investigational flu treatment drug has broad-spectrum potential to fight multiple viruses FORT BELVOIR, Va., Jan. 7, 2014 /PRNewswire-USNewswire/ -- BioDefense Therapeutics (BD Tx)--a Joint Product Management office within the U.S. Department of Defense (DoD)--announced the first patient enrolled in the North American Phase 3 clinical trials for favipiravir (T-705a). The drug is an investigational flu treatment candidate with broad-spectrum potential being developed by BD Tx through...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related